Literature DB >> 19902230

Association between basal, squamous cell carcinomas, dysplastic nevi and myotonic muscular dystrophy indicates an important role of RNA-binding proteins in development of human skin cancer.

Alexander Zemtsov1.   

Abstract

Myotonic muscular dystrophy (MMD) is caused by an abnormal function of RNA-binding proteins (RBP) resulting in DNA spliceopathy. A case of a patient, with MMD multiple basal and squamous cell carcinomas and dysplastic nevi, is described. The association between MMD and non-melanoma skin cancer has been reported before; however, this association was described before the genetic defect of myotonic dystrophy has been fully elucidated. The author proposes a genetic mechanism on how abnormal function of RBP can result or contribute to the development of human skin cancer and propose an explanation for this association between MMD and cutaneous carcinogenesis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19902230     DOI: 10.1007/s00403-009-0997-8

Source DB:  PubMed          Journal:  Arch Dermatol Res        ISSN: 0340-3696            Impact factor:   3.017


  8 in total

1.  Cancer risk among patients with myotonic muscular dystrophy.

Authors:  Shahinaz M Gadalla; Marie Lund; Ruth M Pfeiffer; Sanne Gørtz; Christine M Mueller; Richard T Moxley; Sigurdur Y Kristinsson; Magnus Björkholm; Fatma M Shebl; James E Hilbert; Ola Landgren; Jan Wohlfahrt; Mads Melbye; Mark H Greene
Journal:  JAMA       Date:  2011-12-14       Impact factor: 56.272

2.  Pigmentation phenotype, photosensitivity and skin neoplasms in patients with myotonic dystrophy.

Authors:  S M Gadalla; J E Hilbert; W B Martens; S Givens; R T Moxley; M H Greene
Journal:  Eur J Neurol       Date:  2017-03-20       Impact factor: 6.089

3.  Multiple basal cell carcinomas in a patient with myotonic dystrophy type 1.

Authors:  Jessica Feng; Avery LaChance; David A Sinclair; Maryam M Asgari
Journal:  BMJ Case Rep       Date:  2019-03-08

4.  Correlates of tumor development in patients with myotonic dystrophy.

Authors:  Maya Das; Richard T Moxley; James E Hilbert; William B Martens; Lisa Letren; Mark H Greene; Shahinaz M Gadalla
Journal:  J Neurol       Date:  2012-05-23       Impact factor: 4.849

5.  Risk of skin cancer among patients with myotonic dystrophy type 1 based on primary care physician data from the U.K. Clinical Practice Research Datalink.

Authors:  Youjin Wang; Ruth M Pfeiffer; Rotana Alsaggaf; Wilhelmine Meeraus; Julia C Gage; Lesley A Anderson; Renée C Bremer; Nikoletta Nikolenko; Hanns Lochmuller; Mark H Greene; Shahinaz M Gadalla
Journal:  Int J Cancer       Date:  2017-11-20       Impact factor: 7.396

6.  Cancer risk among patients with hereditary muscular dystrophies: a population-based study in Taiwan, 1997-2009.

Authors:  Gen-Min Lin; Yi-Hwei Li
Journal:  Chin J Cancer       Date:  2014-01-02

7.  Cancer-related genes in the transcription signature of facioscapulohumeral dystrophy myoblasts and myotubes.

Authors:  Petr Dmitriev; Ulykbek Kairov; Thomas Robert; Ana Barat; Vladimir Lazar; Gilles Carnac; Dalila Laoudj-Chenivesse; Yegor S Vassetzky
Journal:  J Cell Mol Med       Date:  2013-12-17       Impact factor: 5.310

8.  Hemangiomas of the tongue and the oral cavity in a myotonic dystrophy type 1 patient: A case report.

Authors:  Simona Portaro; Antonino Naro; Claudio Guarneri; Giuseppe Di Toro; Alfredo Manuli; Rocco Salvatore Calabrò
Journal:  Medicine (Baltimore)       Date:  2018-11       Impact factor: 1.817

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.